Breaking News

Vaccibody Gets $2.5 Million Cancer Grant

November 12, 2012

Will develop cervical cancer vaccine

Vaccibody has received a $2.5 million grant from the Norwegian Research Council’s BIA Program to develop a therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company’s Vaccibody DNA vaccine platform, which targets antigen-presenting cells.
 
“We believe that there is a clear role for an easy-to-administer therapeutic vaccine and that our platform is the ‘missing link’ in DNA vaccines,” said Vaccibody chief executive officer Ole Henrik Brekke. “Firstly by targeting antigen-presenting cells we get a faster and longer lasting immune response at a lower dose than traditional vaccines. Secondly, unlike Dendreon, there is no need to extract patient cells, rather we just use a simple DNA or protein subunit vaccine, which attracts, ligates and activates the antigen-presenting cells by itself. Combined with the 875,000 euros raised from the Sarsia Fund, Radium Hospital Foundation and private investors, this new grant will enable us to take VB10.16 through to clinical trials in early 2014.”
 
The company is also studying its vaccine platform as a therapeutic in B-cell lymphoma, melanoma and other cancer models, as well as a preventive influenza vaccine in a protein format.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials